Free tool
FAERS Monitor: Cetrotide
Last checked: Nov 21, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021197 or its brand name (Cetrotide, Cetrorelix Acetate). Reports on generic versions are filed under their own applications.
Reports
634
Serious
439
69% of reports
Hospitalization
218
Death reported
7
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- ovarian hyperstimulation syndrome136
- drug ineffective45
- premature ovulation41
- abortion spontaneous39
- abdominal distension30
- off label use29
- ascites28
- abdominal pain26
- condition aggravated25
- nausea24
- drug interaction21
- generalised tonic-clonic seizure21
- headache21
- drug level decreased20
- dizziness19
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2005 | 2 |
| 2006 | 4 |
| 2007 | 8 |
| 2008 | 6 |
| 2009 | 16 |
| 2010 | 8 |
| 2011 | 17 |
| 2012 | 18 |
| 2013 | 16 |
| 2014 | 14 |
| 2015 | 33 |
| 2016 | 27 |
| 2017 | 55 |
| 2018 | 58 |
| 2019 | 94 |
| 2020 | 58 |
| 2021 | 34 |
| 2022 | 31 |
| 2023 | 32 |
| 2024 | 33 |
| 2025 | 30 |
| 2026 | 40 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,525 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| premature ovulationSignal | 41 | 36797.4 | 23756.6 | 698,278 |
| ovarian hyperstimulation syndromeSignal | 136 | 2055.6 | 1761.0 | 261,110 |
| drug level decreasedSignal | 20 | 65.3 | 42.4 | 1,201 |
| generalised tonic-clonic seizureSignal | 21 | 42.2 | 27.7 | 803 |
| abortion spontaneousSignal | 39 | 32.3 | 23.8 | 1,154 |
| ascitesSignal | 28 | 31.6 | 22.0 | 800 |
| abdominal distensionSignal | 30 | 9.5 | 6.7 | 222 |
| drug interactionSignal | 21 | 4.4 | 2.9 | 52 |
| abdominal painSignal | 26 | 3.7 | 2.5 | 49 |
| condition aggravatedSignal | 25 | 2.7 | 1.9 | 26 |
| dizziness | 19 | 1.3 | 0.8 | 1 |
| drug ineffective | 45 | 1.1 | 0.9 | 1 |
| headache | 21 | 1.1 | 0.7 | 0 |
| off label use | 29 | 1.1 | 0.8 | 0 |
| nausea | 24 | 1.0 | 0.7 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.